AstraZeneca Beats 2Q Expectations on Oncology, Rare Disease Growth

RCL -2.24% BA -0.79% ARLP -0.28% UL +0.30% MCO -0.59% 6 more

1. 1AstraZeneca (AZN) posted 2Q results above market expectations, driven by growth in its oncology and rare disease units, sending shares higher.
2. 2First-half 2026 revenue rose 9% to $30.7 billion, with core EPS up 12% to $5.21, and the company lifted its interim dividend by 3 cents to $1.06 per share.
3. 3The CARDIO-TTRansform trial failure wiped out more than 11% of enterprise value, but CEO Soriot reaffirmed full-year guidance, saying the company remains on track for its $80 billion revenue target.

Source Proactive +7 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →